Century Therapeutics Inc. (IPSC)
Century Therapeutics Inc. (IPSC) Stock Price, Analysis & Data
| Bid | 1.41 |
| Market Cap | 353.1M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.79M |
| Beta | 1.60 |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.31 |
| P/B (ttm) | 1.33 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 2.45 |
| Volume | 413,881 |
| Avg. Volume (20D) | 1,244,104 |
| Open | 1.92 |
| Previous Close | 1.92 |
| Day's Range | 1.91 - 1.95 |
| 52-Week Range | 0.43 - 3.04 |
| Analyst | Buy |
| Price Target | 4.5 (130.77%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-...
Financial Performance
In 2025, Century Therapeutics's revenue was 109.16M, an increase of 1,556.76% compared to the previous year's 6.59M. Earnings were -9.58M, a decrease of -92.43%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for IPSC stock is "Buy". The 12-month stock price forecast is 4.5, which is upside of 130.77% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
